Stocktoria
Sun Pharmaceutical Industries Limited SUNPHARMA.NS
IN · National Stock Exchange of India · XNSE · stock · Healthcare · website
Sun Pharmaceutical Industries Limited financials (annual)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹582.2B | ₹520.4B | ₹477.6B | ₹432.8B |
| Gross profit | ₹450.5B | ₹398.4B | ₹356.9B | ₹313.4B |
| SG&A expense | ₹114.8B | ₹103.0B | ₹92.2B | ₹80.4B |
| Operating income | ₹135.9B | ₹125.8B | ₹104.7B | ₹92.8B |
| Interest expense | ₹3.4B | ₹2.3B | ₹2.4B | ₹1.7B |
| Income tax | ₹35.5B | ₹27.7B | ₹14.4B | ₹8.5B |
| Net income | ₹114.8B | ₹109.3B | ₹95.8B | ₹84.7B |
| EPS (diluted) | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 |
| Operating cash flow | ₹124.2B | ₹140.7B | ₹121.3B | ₹49.6B |
| Free cash flow | ₹88.1B | ₹119.4B | ₹99.3B | ₹28.7B |
| Cash & equivalents | ₹97.7B | ₹102.7B | ₹92.9B | ₹46.2B |
| Inventory | ₹114.9B | ₹102.4B | ₹98.7B | ₹105.1B |
| Goodwill | ₹98.3B | ₹89.4B | ₹85.7B | ₹83.6B |
| Total assets | ₹1.09T | ₹921.0B | ₹855.0B | ₹807.4B |
| Total debt | ₹46.3B | ₹23.6B | ₹32.7B | ₹68.9B |
| Total liabilities | ₹249.1B | ₹196.1B | ₹183.7B | ₹214.3B |
| Shareholders' equity | ₹835.7B | ₹722.2B | ₹636.7B | ₹560.0B |
| Share buybacks | ₹38.0M | ₹29.0B | ₹773.9M | ₹0 |
Growth · year-over-year · Revenue CAGR 10.4%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +11.9% | +9.0% | +10.4% | — |
| Net income growth | +5.0% | +14.1% | +13.0% | — |
| EPS growth | +4.8% | +14.3% | +13.0% | — |
| Free cash flow growth | -26.2% | +20.2% | +245.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.